> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-115/
- Published: 2018-11-04T12:00:00.000Z
- Updated: 2026-09-15T00:42:23.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5141373

**Novanta** has acquired privately-held **Zettlex Holdings** and its inductive encoders that can provide absolute and accurate positioning even in extreme operating environments. Novanta says there is a growing demand for precision motion technology in robotics, precision automation and key medical markets.

**Janssen Biotech** has agreed to purchase **HC2 Holdings** in a deal that could be worth more than $1 billion. The transaction give Janssen the rights to **BeneVir’s proprietary T-Stealth Oncolytic Virus Platform** that can be used to develop oncolytic viruses used to infect and destroy cancer cells.

**United Therapeutics** has agreed to acquire **SteadyMed** for $216 million. , including $75 million in contingent consideration. The transaction gives United Therapeutics access to SteadyMed’s experimental combination therapy Trevyent for the subcutaneous treatment of pulmonary arterial hypertension.

**Biomerics** and **ATL Technology** have entered into a joint venture to acquire **Catheter Research**’s assets, which include interventional catheters, tube sets, and other assemblies for medical devices with expertise in tube extrusion, catheter assembly, and final FDA product packaging for sterilization. Catheter Research services original equipment manufacturer customers as well as sell their own catheter line under the Thomas Medical brand.